Thomson Reuters can provide the knowledge, tools and expertise to help support your drug discovery and development activities, optimize your IP portfolio, identify licensing and partnering opportunities, deliver successful regulatory submissions, keep you in touch with the rapidly-changing pharmaceutical and chemical markets, and make informed, early decisions.

Connect with us on Facebook and Twitter

WEBINARS

IDRAC EGYPT MODULE WEBINAR

Join us to understand the local regulatory practices and requirements to enter the Egypt market. This webinar will showcase the data available for the Egypt within following areas 'organization of authorities, legal framework, the drug development and registration processes, product information, clinical research, quality assurance, pricing and reimbursement', and will provide a current overview of the Egypt regulatory environment. Tuesday, February 14, 9AM EST. Register Now

NEWS

Thomson Reuters Helps Brazil's Institute for Applied Economic Research Identify New Opportunities in the Generic Drug Landscape

This partnership provides IPEA's Direction of Sectorial Studies and Policies for Innovation, Regulation and Infrastructure branch with access to the Newport suite of products, supplying them with generic pharmaceutical intelligence as well as with tools for business development and the sourcing of global active pharmaceutical ingredients. Read the Press Release

SPOTLIGHT ON... DIABETES

This quarter's Spotlight On... Report focuses on the Diabetes market – new entrants to the market and the increase in market value. The diabetes market is currently one of the biggest value and fastest growing in the pharma industry, fueled by the vast number of patients needing pharmaceutical intervention to control their disease. Learn More

Generic Drug User Fee Act -- Who Will Benefit?

Bob Kennedy, Manager of Industry Research at Thomson Reuters, recently wrote in CHEManager Europe about the proposed Generic Drug User Fee Act (GDUFA), and who will be affected by the changes. Read the article

Thomson Reuters to Work with Michael J. Fox Foundation to Map the Pathways for Parkinson's Disease

The project aims to identify possible causes of Parkinson's by mapping biological mutations of the Leucine-rich repeat kinase 2 (LRRK2) protein, the most common genetic contributor to the disease discovered to date. The maps will trace the disease's biological pathways to pinpoint relevant biomarkers, which are biological molecules that signal an abnormal process or disease. Read More -- Learn About MetaCore

THE CHANGING ROLE OF CHEMISTRY IN DRUG DISCOVERY

This new report celebrating the end of the International Year of Chemistry 2011 delivers an action packed review of the changing role of the Chemist in today's Pharmaceutical Research.  Learn More

The Ones To Watch

The latest edition of The Ones To Watch is now available, covering the most promising drugs changing clinical phase, receiving approval and launched between July - September 2011.  Learn More

INTRODUCING CORTELLIS FOR COMPETITIVE INTELLIGENCE

Find the best opportunities for growth and development with the most accurate and timely competitive intelligence tool in Cortellis. Drug pipelines, deals, patents, companies, breaking industry news, and conference coverage in one source, so you can make the best decisions for growth, faster. Learn more

Search Our Free Pathway Maps

Signaling pathways are the communication highways inside a cell. Like circuitry in a machine, pathways carry important impulses that control all cell functions. The hunt for new and better medicines truly starts here. Please visit our site, www.pathwaymaps.com, to have a taste of some of the 1,200 proprietary multi-step canonical pathway maps contained in MetaCore™.